Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:11:54.344Z.
Consensus retrieved: 2026-10-06T11:08:46.662Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:11:54.344Z.
Quote observation: 2026-10-06T16:10:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: df0d51bc4c7c4fe031789de0e9442acf829cec50a05ec95901a80cda74a8a9f3
Forward PE Ratio (N/A) = Dated Quote Price ($42.87) / Consensus Forward EPS ($-1.84)
FORWARD PE RATIO
N/A
Enliven Therapeutics, Inc.
Market Cap
$3.06B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | $3.06B | N/A |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.08B | N/A |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.08B | 49.50 |
| Denali Therapeutics Inc. (DNLI)vs › | $3.14B | N/A |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.87B | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.82B | 55.64 |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.34B | N/A |
| AtriCure, Inc. (ATRC)vs › | $2.80B | N/A |
| Precigen, Inc. (PGEN)vs › | $2.74B | 44.79 |
| CareDx, Inc (CDNA)vs › | $3.42B | 55.16 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $42.87, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.84 | $-2.49 – $-1.35 | 7 | n/m |
| 2027-12-31 | $-2.29 | $-2.45 – $-1.94 | 7 | n/m |
| 2028-12-31 | $-2.83 | $-3.30 – $-2.26 | 9 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
